In a third-generation in vivo test, cells with a CD8 TM or a 4-1BB TM displayed similar, modest antitumor activities, whereas cells with an ICOS TM induced 100% tumor regression within 35 days in NSG mice. Here, CD8A is linked to neoplasm.